Recommendation of the President – Beyonttra (akoramidis)
On 2 March 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 32/2026 on the reimbursement of the medicinal product Beyonttra (akoramidis) under the B.162 drug program “Treatment of patients with cardiomyopathy (ICD-10: E85, I42.1)”